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Abstract
The increasing complexity and high amount of dose per fraction delivered in prostate high dose rate
(HDR) brachytherapy treatments call for the implementation of accurate and effective methods for the
systematic and independent quality control of the overall treatment procedure. In this study, MOSkin
detectors were placed on a trans-rectal ultrasound (TRUS) probe with the aim of performing both imaging
and real time rectal wall in vivo dosimetry with the use of just one single instrument. After an adequate
calibration of the detectors, which was carried out in a solid water phantom, the use of MOSkins
integrated to the TRUS probe was studied in a gel phantom with a typical (simplified) prostate implant.
Measured and calculated doses from the treatment planning system were compared, with a resulting very
low average discrepancy of -0.6 ± 2.6%. The results are very promising and of particular clinical
importance, however, further in vivo investigation is planned to validate the proposed method.
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ABSTRACT
The increasing complexity and high amount of dose per fraction delivered in prostate high dose rate
(HDR) brachytherapy treatments call for the implementation of accurate and effective methods for
the systematic and independent quality control of the overall treatment procedure. In this study,
MOSkin detectors were placed on a trans-rectal ultrasound (TRUS) probe with the aim of performing
both imaging and real time rectal wall in vivo dosimetry with the use of just one single instrument.
After an adequate calibration of the detectors, which was carried out in a solid water phantom, the
use of MOSkins integrated to the TRUS probe was studied in a gel phantom with a typical (simplified)
prostate implant. Measured and calculated doses from the treatment planning system were
compared, with a resulting very low average discrepancy of 0.6 ± 2.6%. The results are very
promising and of particular clinical importance, however, further in vivo investigation is planned to
validate the proposed method.
1. Introduction
Brachytherapy (BT) delivers an extremely conformed high dose to the prostate, using either a low
dose rate or a high dose rate (HDR) technique (Morton and Hoskin, 2013). With HDR, a single high
activity source of short-range radiation (e.g., Ir-192) is remotely moved to predefined positions via
temporarily needles that are implanted within the target. By adjusting the source dwell times in each
one of the planned dwell positions, a tailored and customized dose distribution can be achieved to
ensure optimal coverage of the defined treatment volume.
Nevertheless, HDR BT is a meticulous technique and procedural variations caused by factors such as
patient motion, needle movements, anatomical changes occurring between imaging and treatments,
as well as potential human inaccuracies or errors, may lead to a significant degradation of the plan
(Thomadsen et al., 2003). Therefore, to ensure the delivered dose agrees within acceptable limits to
that planned, rigorous quality assurance (QA) procedures should be implemented for independent
treatment verification. In particular, effective and accurate QA methods need to be developed,
as the complexity of BT delivery has rapidly increased (Palmer et al., 2012; Tanderup et al., 2013)
and new highly fractionation schemes (i.e., 26-27Gy in two fraction or 19-21Gy in one single fraction)
have recently been introduced (Morton and Hoskin, 2013).
In vivo dosimetry represents a useful QA tool, not only for avoiding treatment misadministration, but
also for evaluating doses to organs at risk (i.e., urethra, rectum and bladder). Moreover, if
performed on-line, it allows the constant monitoring of the dose delivered during the treatment,
enabling the immediate intervention of the clinician if adverse dose readings are detected (Lambert
et al., 2007).
A number of different systems to perform in vivo dosimetry have been developed, including passive
integrating thermoluminescent dosimeters (TLDs) and active methods based on diodes, diamond
detectors, optical fiber-coupled scintillators and MOSFETs (Fagerstrom et al., 2008; Rustgi, 1998;
Toye et al., 2009; Waldhäusl et al., 2005; Zilio et al., 2006). Some of these have already been used to
perform in vivo prostate dosimetry by directly placing them in either a needle in the prostate, a

catheter in the urethra or in the rectum (Seymour et al., 2011; Suchowerska et al., 2011). As the
trans-rectal ultrasound (TRUS) probe is one possible means of performing real time prostate HDR BT
treatment planning, it would be advantageous to include dosimeters to the probe so that the probe
itself would represent a tool for both imaging and in vivo rectal wall dosimetry. This system would in
fact be particularly convenient, avoiding the insertion of extra invasive catheters or needles for the
positioning of the detectors. In this study, a particular type of MOSFET dosimeters, MOSkins, were
integrated to the TRUS probe, with phantom measurements of prostate brachytherapy implants
performed.
2. Materials and Methods
2.1 MOSkin dosimeters and the brachytherapy facility
MOSkin detectors are particular type of MOSFET devices recently developed by the Centre for
Medical Radiation Physics (CMRP), University of Wollongong, Australia. They are characterized by
their novel packaging technology used to seal the sensor chip, which differentiates them from other
commercial MOSFETs and makes them more suitable for dose measurements in steep dose
gradients and for skin dosimetry. Their sensitive volume, defined by the volume of the gate oxide, is
4.8 x 10-6mm3. More specific information about MOSkin dosimeters may be found elsewhere (Qi et
al., 2007; Kwan et al., 2009).
All the measurements in this study were carried out with a microSelectron-HDR remote afterloader
device (Nucletron, Veenendaal, The Netherlands) provided with an Ir-192 source with active length
of 3.6mm and diameter of 0.65mm. The source is contained in a stainless steel capsule, laser welded
to a steel cable for its remote positioning at required locations into the treatment catheters/needles.
2.2 MOSkin calibration with the Ir-192 brachytherapy source
MOSkin detectors calibrations were performed in a water-equivalent phantom constructed with
several solid water slabs of various thickness placed in a stacked configuration to provide adequate
backscatter conditions. One MOSkin at a time was positioned at the center of the phantom and was
oriented with its sensitive volume in source direction.
A plastic needle for source positioning was inserted in the phantom with its centre at a distance of
21 ± 0.1mm from the MOSkin detector. To irradiate the detector, a single source dwell position was
chosen right above the MOSkin (i.e., nearest point of the source catheter to the dosimeter) (Fig.1). In
order to ensure that the response uncertainty associated with the MOSkin reader (±1mV) was less
than 1% of the threshold voltage change, a dwell time of 78s was chosen. Each detector was
irradiated three times and the corresponding voltage threshold measurements Vi were recorded and
averaged to Vmean. The delivered dose at the calibration position Dcal was then calculated by a
means of a commercial BT treatment planning system (TPS) (Oncentra Prostate, Nucletron, The
Netherlands) which complies with the American Association of Physicists in Medicine (AAPM) TG-43
dose calculation formalism (Rivard et al., 2004). The calibration factor, N, was determined as
N=Dcal/Vmean, given in cGy/mV.

Fig 1. Schematics of the experimental setup. A) The MOSkin detector was placed in the centre of the water-equivalent phantom. The
orthogonal distance to the source catheter was of 21 mm. B) During irradiation, the single dwell position of the Ir-192 source was chosen
in correspondence to the closest distance to the MOSkin detector (i.e. 21mm).

2.3 Transrectal ultrasound-based prostate HDR brachytherapy
Prostate ultrasound imaging by means of a TRUS probe is one of the possible image guidance
modalities used to both guide the insertion of needles through the perineum and plan HDR BT
treatments. Its use instead of CT imaging is constantly increasing (Batchelar et al., 2013). It would
therefore be particularly convenient and effective to attach accurate dosimeters to the TRUS-probe
in order to perform both imaging and real time rectal wall in vivo dosimetry by the use of just one
single instrument.

Fig 2. MOSkin dosimeters, positioned along the longitudinal axis of the probe, at a distance of 25mm and 35mm from the axial transducer,
respectively.

In this study, two MOSkin detectors were integrated to a TRUS probe which is commonly used in
clinical practice. MOSkin detectors were positioned along the longitudinal axis, with an additional
2 mm silicon spacer between them and the surface of the probe. The sensitive surface of each
detector was facing thee target, with positions of d1 = 25mm and d2 = 35mm from
fr
the transversal
transducer, respectively (Fig. 2).
2.4 In phantom dosimetry of prostate brachytherapy treatments
With the aim of performing dose measurements to the rectal wall with MOSkin
MOSkins integrated to the
TRUS probe, a suitable gel phantom was created. The phantom has a cylindrical shape with length
leng of
14.5cm, diameter of 17.6cm
cm and an off-center
off center cavity simulating the rectum. Six interstitial needles
were placed through a template inside the gel phantom over the cavity to reproduce a treatment
implant
mplant (Fig. 3). Through the cavity, US-images
US images were acquired in order to precisely localize needles
and plan a treatment. A virtual prostate was created on the US images around the needles implant
over a total longitudinal length of 25mm.
25
Dose to the virtual
al prostate was optimized and the
expected doses to each dosimeter evaluated. To identify the radial location of the detectors, the
probe-image
image interface was taken as reference (Fig. 4) whereas the positions of the detectors along
the longitudinal axis weree identified at distances d1 and d2 from the base plane.

Fig 3. Schematic representation of the MOSkin
Skin detectors integrated on the TRUSprobe and of the six needles placed through the template
into the gelatin phantom tosimulate a typical (simplified) clinical
cl
distribution.

Fig 4. Ultrasound image of the gelatin phantom with the six implanted needles recognizable on the image. The probe-phantom
probe
interface is
indicated in the image.

During irradiation (total time: 232.1s),
23
the plastic needles were connected to the BT afterloader
device through transfer tubes and MOSkins were connected to the CMRP
RP dosimetry system for onon

line dose measurements. In accordance with the clinical procedure, during irradiation, the TRUS
probe was left inside the phantom and its position was reordered in order to identify the position of
the detectors. Three measurements in the same irradiation set-up were performed. The resulting
measured doses were averaged and compared to the predicted doses in the detector positions on
the plan.
3. Results and Discussion
3.1 MOSkin calibration with the Ir-192 brachytherapy source
The resulting calibration factors for the two employed dosimeters were 0.41 ± 0.01cGy/mV and 0.40
± 0.01cGy/mV. The corresponding detector sensitivities were 2.43mV/cGy and of 2.49mV/cGy,
respectively. Detector sensitivities were similar to those of the MOSkin detectors from other batches
which were 2.17mV/cGy as reported by Qi et al. (2012) and of 2.63mV/cGy as reported in Gambarini
et al. (2014). Differences between these values might be due to intrinsic differences of the structural
and packaging materials between each single dosimeter and to a small sensitivity reduction that
might be observed over the entire life time of the detectors.
Concerning the calibration procedure, it is important to note that the reference dose data to
perform dosimeter calibration were those resulting from the TPS and cross-checked with software
based on the AAPM TG-43 algorithm, rather than those obtained experimentally by the use of a
further dosimeter. The choice was taken in accordance to many other studies reported in literature,
such as Lambert et al. (2006), Therriault-Proulx et al. (2011) and Gambarini et al. (2014). In fact,
factors implemented in the TPS are those tabulated in Daskalov et al. (1998) and are obtained by
means of Monte Carlo photon transport code knowing the characteristics of the specific source
model (i.e., mHDR-v2). Consensus on these factors has been widely accepted and the resulting TPS
calculations are highly accurate when performed in the reference conditions of unbounded
water/water-equivalent medium.
3.2 In phantom dosimetry of prostate brachytherapy treatments
Table 1. Percentage dose differences between total doses measured by two MOSkin detectors (MOSkin1 and MOSkin2) integrated to the
TRUS probe and the expected doses in the same points calculated with the treatment planning system.
Dose difference (%)
Measure#1
Measure#2
Measure#3
MOSkin 1
0.05
1.3
2.8
MOSkin 2
-4.5
-2.1
-1.4

Fig 5. Dose distribution along the longitudinal direction calculated by means of the treatment planning system (TPS) and doses measured
by the two MOSkins. The light gray dotted lines indicate the dose distributions calculated 0.5mm above and under the probe-phantom
interface, which was chosen as the reference radial position of the MOSkins.

A comparison of total doses measured by MOSkin detectors integrated to the US-probe and the
expected doses in the same points calculated with the TPS are reported in Table 1 for the three
performed treatment sessions of the same plan. Excellent agreement between values has been
observed with a resulting average discrepancy of 0.6 ± 2.6%. Fig. 5 shows the calculated dose
distribution in longitudinal direction and the corresponding average doses measured by the
detectors. Inaccuracy in the identification of the exact dosimeter location was of 0.5mm. Once
MOSkins were calibrated in a reference condition, a more complex arrangement representing a
typical prostate implant was used to investigate the MOSkin detectors in a clinical setup. In fact, with
an accurate and reproducible geometrical disposition of the needles, the study demonstrated that
the MOSkins reproducibility was very high and that possible angular and energy dependences
(Cygler et al., 2006; Zilio et al., 2006; Hardcastle et al., 2010; Qi et al., 2012) do not significantly
affect dose measurements. The obtained results are very promising and of particular clinical
importance. Rather than investigating accuracy of the TPS dose calculation, it is expected that in vivo
clinical application of MOSkin dosimeters to HDR prostate BT treatments will be very important to
discover dose discrepancies due to body movement/anatomy alteration or needle displacement,
which may take place between pre-planning imaging and treatment (Milickovic et al., 2011;Dinkla et
al., 2013;Cherpak et al.,2014). As this was the first instance of real time dose measurements being
performed by integrating dosimeters to the TRUS-probe, the proposed method of dosimetry will be
refined through further investigation.
4. Conclusions
Real-time dosimetry represents an effective tool for avoiding gross inaccuracies during HDR prostate
BT applications. To this aim, MOSkin detectors were integrated to a TRUS probe to perform real time
rectal wall in vivo dosimetry without the need to change instrumentation from the devices used for
imaging and planning. In phantom results have shown excellent agreement between measurements
and calculated data. These results are very promising, however, further in vivo investigation is
required to refine the proposed method.
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